Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering.
The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a system of automated pumps and sensors that fed the organ nutrients, supplied it with blood, and whisked away waste.
In an interview, Pulitano, a transplant surgeon at the Royal Prince Alfred Hospital and a professor at the University of Sydney, likened the life support system to “an artificial body.” Its official name is the Extended Organ Perfusion System.
“Our group is the only one in the world to have maintained a human liver under fully normothermic, physiological conditions for seven weeks,” he says.
Normothermic means body temperature, or about 37 °C. The previous record for keeping an internal organ alive outside the body was set in Switzerland several years ago. That organ—also a liver—lasted around two weeks.
Most organs destined for transplant survive only a few hours in special ice buckets and need to be raced to their destination. Over the last decade, however, surgeons have been switching to perfusion systems, which pump warm or cold fluids into an organ. This can double the time it can be held before it must be transplanted.
Pulitano says the key to breaking the record was to automate the systems used to keep the organ thriving. During a meeting in Switzerland earlier this year, the Sydney team described perfusing 55 human livers, one after the other. Some were connected to a system that needed to be adjusted manually, but for those placed on the automated system—which produced the seven-week survivor—the average survival time tripled, to about four weeks.
Perfusion has already enabled doctors to restart hearts from dead people and keep them beating outside the body. Paulo Martins, a transplant doctor at the University of Oklahoma, says about half the kidneys he transplants are now perfused, even though the process can add $100,000 to the cost of a transplant.
While the research awaits formal publication, the eventual goal is what Pulitano and colleagues call “time-unlimited liver preservation.”
Scientists have already discovered possible medical benefits to keeping organs on life support longer than usual. One, they say, is that perfused organs apparently start to repair themselves and become stronger after a day or so. That’s what led a Swiss team, in 2022, to transplant a damaged liver that had been kept on perfusion for three days—the longest time any internal organ had remained outside the body before a successful transplant, says Waldemar Hoffmann, the CEO and cofounder of Apersys, a startup formed to commercialize the technology.
Pulitano says his own startup, Aeternum Life Technologies, will be helping with a planned trial in Sydney to transplant low-quality livers kept on perfusion for four days.
What’s less clear, says Hoffmann, is whether any transplant surgeon would ever want, or need, to use an organ kept alive for nearly two months. He says people in the field believe Pulitano’s record is real, but they don’t know how healthy the organ was at the end or even what so much extra time is likely to achieve. “The key question is what the purpose for a seven-week perfusion would be,” he says.
Yet that’s where things could start to get interesting, says Martins, the Oklahoma surgeon. Long-term life support could enable far-out concepts like artificial wombs, new types of organ manufacturing, and the chance to experiment directly on human organs outside the body for extended periods.
For his part, Pulitano says long-term machine perfusion could help grow new organs. In living donations, surgeons commonly take half of a person’s liver to give someone else. After about two months, both parts will have grown back almost to their full volume. Pulitano says he’s tried dividing a liver and then attaching the sections to the machine. If that works, he says, it could be a way to multiply one donor liver into several full-size organs.
“It’s important to have people thinking outside the box and pushing the limits and creating possibilities for things that, right now, sometimes we don’t even have a need for but are going to be needed in the future,” says Martins. “That’s how science moves.”
He’s not the only one who thinks so. For instance, a US company, Bexorg, has been reanimating human brains using perfusion pumps. The idea is to study what effects experimental drugs have on them. That company perfuses brains for about a day but has said it wants to extend the time to two weeks.
Similar experiments can be done on livers, says Pulitano, who has already tried adding gene therapies to the organs. “It gives us a living human organ model for translational research that no animal system can match, because the biology, the immunology, and the drug responses are human from the outset,” he says.
Meanwhile, in Silicon Valley, patents filed by Altos Labs, a billionaire-backed longevity startup, describe attempts to introduce reprogramming genes into animal livers maintained outside the body. Eventually, Altos scientists have speculated, they might temporarily disconnect a failing organ while it’s still in a person’s body, connecting it to a perfusion machine in order to douse it with ultra-powerful genetic treatments without risking the rest of the body.
Doctors probing the limits of organ life support have now formed two new scientific societies to explore the concept. One, founded by Martins and called the International Society for Organ Preservation and Perfusion Therapy, will hold its inaugural meeting this year in Italy. The other, based in China, was launched in August to advance what doctors at the First Affiliated Hospital of Sun Yat-Sen University have termed “organ medicine”: research at the level of whole organs kept alive by “bionic maintenance.”
“What is exploding is the idea of this technology that clearly goes beyond simply organ preservation,” says Pulitano. “Basically, that’s a concept that’s entirely new.”
